MMIP briefing paper: The fiscal benefits of establishing and retaining medicine manufacture in the UK

This is my final CEO update in Newscast after 13 years at the BIA. I take up my new role as Executive Chair of the Office for Life Sciences next Monday. Before I do, I want to thank you - my loyal readers - for engaging with my musings over the years, and for your feedback that has improved this blog and my thinking.

Abzena has announced the expansion of our AbZelectPRO™ cell line development (CLD) platform with the launch of two next-gen Glutamine Synthetase (“GS”) knockout CHO-K1 expression systems, including a double knockout ADCC+ platform for afucosylated proteins.

Asymchem, has announced a significant expansion of its flow chemistry capabilities at its Sandwich, UK facility.

Cotton Mouton Diagnostics (CMD), a cutting-edge UK-based diagnostics technology company, has received a half-a-million-pound investment from CPI Enterprises as part of the Innovate UK Catapult Investment Pilot.

 In this blog, Abby Clark builds on a round table the BIA hosted with Chi Onwurah MP and Newcastle life science companies to explore the landscape and the drivers which make the sector strong, yet undervalued.